Journal
CANCER CELL
Volume 6, Issue 5, Pages 517-527Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2004.09.031
Keywords
-
Categories
Ask authors/readers for more resources
Given the role of the EGFR/HER2 family of tyrosine kinases in breast cancer, we dissected the molecular basis of Ill HER2 kinase signaling in prostate cancer. Using the small molecule dual EGFR/HER2 inhibitor PKI-166, we show that the biologic effects of EGFR/HER-2 pathway inhibition are caused by reduced AIR transcriptional activity. Additional genetic and pharmacologic experiments show that this modulation of AIR function is mediated by the HER2/ERBB3 pathway, not by EGFR. This HER2/ERBB3 signal stabilizes AIR protein levels and optimizes binding of AIR to promoter/enhancer regions of androgen-regulated genes. Surprisingly, the downstream signaling pathway responsible for these effects appears to involve kinases other than Akt. These data suggest that the HER2/ERBB3 pathway is a critical target in hormone-refractory prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available